Impact of new pharmacological strategies for the treatment of acute myocardial infarction: study of the effects and synergy of sacubitril/valsartan and empagliflozin
[eng] INTRODUCTION: The introduction of new drugs such as sacubitril/valsartan and empagliflozin has markedly improved clinical outcomes in patients with heart failure (HF). The role of these drugs in HF is well-established; however, their efficacy on post-acute myocardial infarction (AMI) remains l...
| Autor: | |
|---|---|
| Tipo de recurso: | tesis doctoral |
| Estado: | Versión publicada |
| Fecha de publicación: | 2025 |
| País: | España |
| Institución: | Universidad de Barcelona |
| Repositorio: | Dipòsit Digital de la UB |
| OAI Identifier: | oai:diposit.ub.edu:2445/221664 |
| Acceso en línea: | https://hdl.handle.net/2445/221664 http://hdl.handle.net/10803/694698 |
| Access Level: | acceso abierto |
| Palabra clave: | Cardiologia Malalties cardiovasculars Anàlisi de medicaments Inflamació Arrítmia Cardiology Cardiovascular diseases Drugs analysis Inflammation Arrhythmia |
| Sumario: | [eng] INTRODUCTION: The introduction of new drugs such as sacubitril/valsartan and empagliflozin has markedly improved clinical outcomes in patients with heart failure (HF). The role of these drugs in HF is well-established; however, their efficacy on post-acute myocardial infarction (AMI) remains largely unexplored. Limited evidence exists on the safety and the potential synergistic effects when combining empagliflozin with sacubitril/valsartan post-AMI. HYPOTHESIS: The early administration of empagliflozin and/or sacubitril/valsartan after MI may exert a protective role against post-ischemic injury by reducing inflammation and oxidative stress, enhancing cardiac metabolism, and/or providing protective effects on post-AMI structural and electrical remodelling. The combination of both drugs could be safe and may have a synergistic effect. OBJECTIVES: To evaluate the cardiac impact of early initiation of empagliflozin and/or sacubitril/valsartan on inflammation, oxidative stress, metabolism, myocardial fibrosis, cardiac function, electrophysiological and histological scar properties, and ventricular tachycardia (VT) inducibility in an AMI pig model. |
|---|